Condition: Systemic Sclerosis (SSc) · ANCA Associated Vasculitis (AAV) · Idiopathic Inflammatory Myopathy (IIM) · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this study is to investigate the safety and efficacy of Anti-CD19 IL-10/IL15 CAR-NK cells in patients with refractory/relapsed autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myositis, ANCA associated vasculitis, sjogren syndrome, and antiphospholipid syndrome.
This description comes directly from the study's public registry record.
Jing Xue, MD., · +86-13758121751 · jingxue@zju.edu.cn
Always discuss trial participation with your own doctor first.
| the second affiliated hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06614270